乳腺正电子发射成像PUVmax在非肿块强化恶性病变中的应用
该前瞻性研究评估乳腺正电子发射成像(PEM)峰值摄取值(PUVmax)作为功能生物标志物的价值,纳入154例MRI检出BI-RADS 4-5类非肿块强化(NME)且手术病理证实的恶性肿瘤患者。PUVmax≥4.1可界定高危生物学表型,与手术病理符合率达97.4%,且与高危/高增殖表型显著相关。
要点
- PUVmax≥4.1可界定高危生物学表型,适用于浸润性癌和导管原位癌。
- PEM对穿刺-手术不一致病例的正确再分类率达84.6%,有助于减少低估。
- 观察者间一致性极佳,ICC为0.94,PUVmax测量可重复性好。
核心结论
- PEM衍生的PUVmax与手术病理符合率高,可作为恶性NME高危生物学特性的全病灶功能生物标志物。
研究设计与样本
- 前瞻性研究,纳入2023年3月至2025年3月间MRI检出BI-RADS 4-5类NME的患者。
- 246例评估患者中排除92例后,最终纳入154例组织学确诊恶性肿瘤且有手术病理的患者。
- 全部患者先行超声引导空心针穿刺活检,再行手术切除;PEM于活检前(n=91)或活检后至少2周(n=63)进行。
关键影像表现/征象
- PEM为乳腺专用正电子发射成像,PUVmax反映病灶整体代谢摄取的峰值水平。
- 非肿块强化(NME)为MRI上的强化形态类别,对应BI-RADS 4-5类判读。
诊断标准与关键数值
- PUVmax≥4.1界定为高危生物学表型。
- PEM与手术病理符合率为97.4%,假阴性4例(2.6%),无假阳性。
- 穿刺-手术不一致发生率为16.9%(26/154),其中升级24例,PEM识别20/24例升级(83.3%)。
- PEM对穿刺-手术不一致病例的正确再分类率为84.6%。
临床应用与阅片要点
- PUVmax≥4.1提示高危生物学表型,可辅助判断病灶整体风险,减少穿刺取样不足导致的低估。
- PEM可作为MRI检出NME后、活检病理与影像不符时补充的功能影像手段。
- PUVmax测量观察者间一致性极佳,适合纳入日常报告标准化评估。
局限性
- 本研究为单中心设计。
- PEM在活检后进行者需间隔至少2周,可能受活检后改变影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: To evaluate peak uptake value (PUVmax) derived from positron emission mammography (PEM) as a functional biomarker for identifying high-risk/high-proliferation phenotypes and addressing biopsy sampling limitations in malignant non-mass enhancement (NME).
METHODS: This prospective study included patients with MRI-detected Breast Imaging Reporting and Data System (BI-RADS) 4-5 NME between March 2023 and March 2025. Of 246 patients assessed, 92 were excluded because of benign pathology, planned neoadjuvant therapy, incomplete histopathological data, or unavailable surgical outcomes, leaving 154 patients with histologically confirmed malignancy and surgical pathology. All underwent ultrasound-guided core-needle biopsy followed by surgical excision. PEM was performed before biopsy (n = 91) or at least 2 weeks afterward (n = 63). PUVmax was measured, with ≥4.1 defining a high-risk biological phenotype. Interobserver agreement was assessed using the intraclass correlation coefficient (ICC). Receiver operating characteristic curve, multivariable logistic regression, and reclassification analyses were performed.
RESULTS: Interobserver agreement was excellent (ICC = 0.94). Biopsy-surgical discordance occurred in 26/154 cases (16.9%), mainly upgrades (24/26). PEM identified 20/24 upgrades (83.3%). Concordance between PEM and surgical pathology was 97.4%, with 4 false-negative cases (2.6%) and no false positives. PUVmax was significantly associated with high-risk/high-proliferation phenotype (odds ratio = 2.89, 95% CI, 1.95-4.28; P < .001; AUC = 0.86).
CONCLUSION: PEM-derived PUVmax shows high concordance with surgical pathology and may provide a reliable whole-lesion functional biomarker of high-risk biology in malignant NME.
ADVANCES IN KNOWLEDGE: A PUVmax threshold ≥4.1 distinguished low- from high-risk disease across invasive carcinoma and ductal carcinoma in situ. PEM correctly reclassified 84.6% of biopsy-surgical discordant cases, potentially reducing underestimation caused by limited biopsy sampling of biologically heterogeneous lesions.
引用
- Emad, Sobhi, Wessam, et al. Peak uptake value on positron emission mammography addresses biopsy sampling limitations in stratifying proliferative activity of malignant non-mass enhancement. Br J Radiol. 2026. PMID: 42596586. doi:10.1093/bjr/tqag188
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。